CHMP gives positive opinion for licence extension for secukinumab (Cosentyx)

The CHMP have recommended a licence extension for use of secukinumab for non-radiographic axial spondyloarthritis in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs.

European Medicines Agency